Milavetz B I, Horoszewicz J S, Rinehart K L, Carter W A
Antimicrob Agents Chemother. 1978 Mar;13(3):435-40. doi: 10.1128/AAC.13.3.435.
A series of structurally related ansamycins have been analyzed, in a new immobilized template assay, to determine the mechanism by which they inhibit a ribonucleic acid-directed deoxyribonucleic acid (DNA) polymerase from Moloney murine leukemia virus. By this assay, we can better correlate specific structures of these drugs with inhibitory mechanisms. Using an immobilized template, we were also able to observe drug effects on the stability of complexes formed between the polymerase, a template (polyadenylic acid-agarose), and a primer, as well as to monitor the synthesis of DNA in the presence of drug. For each drug, we determined the complex (intermediate in DNA synthesis) which was primarily affected and whether the effect was due to a destabilization process. Although the activity and specificity of the unsubstituted ansamycins (streptovaricins and rifamycin SV) were modulated by conformation of the molecule and electron density of the aromatic ring, the principal mode of inhibition is, apparently, drug binding to a polymerase-template complex; the drug binds in a manner which prevents subsequent formation of a polymerase-template-primer complex. However, some derivatives of rifamycin SV, when substituted at carbon-3 with bulky or hydrophobic side chains, displayed markedly different modes of action. For example, demethyl dimethyl rifampin prevented the formation of polymerase-template complexes, whereas rifazacyclo 16 acted by promoting the dissociation of polymerase-template-primer complexes.
在一项新的固定化模板试验中,对一系列结构相关的安莎霉素进行了分析,以确定它们抑制莫洛尼氏鼠白血病病毒的核糖核酸指导的脱氧核糖核酸(DNA)聚合酶的机制。通过该试验,我们可以更好地将这些药物的特定结构与抑制机制联系起来。使用固定化模板,我们还能够观察药物对聚合酶、模板(聚腺苷酸 - 琼脂糖)和引物之间形成的复合物稳定性的影响,以及监测药物存在下DNA的合成。对于每种药物,我们确定了主要受影响的复合物(DNA合成中间体)以及该影响是否是由于去稳定化过程。尽管未取代的安莎霉素(链黑菌素和利福霉素SV)的活性和特异性受分子构象和芳香环电子密度的调节,但主要的抑制模式显然是药物与聚合酶 - 模板复合物结合;药物以阻止随后形成聚合酶 - 模板 - 引物复合物的方式结合。然而,利福霉素SV的一些衍生物,当在碳 - 3处被庞大或疏水侧链取代时,表现出明显不同的作用模式。例如,去甲基二甲基利福平阻止聚合酶 - 模板复合物的形成,而利福杂环1号通过促进聚合酶 - 模板 - 引物复合物的解离起作用。